ERG and prostate carcinoma: In addition, TMPRSS2-ERG fusion is present in 40%–80% of prostate cancers, overexpression of estrogen-regulated gene (ERG) due to gene fusion is associated with a more aggressive phenotype in prostate cancer [31, 32].